FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2262425995> ?p ?o ?g. }

• W2262425995 endingPage "265" @default.
• W2262425995 startingPage "241" @default.
• W2262425995 abstract "Conclusions and PerspectivesAs outlined herein, there is now much evidence that increased Rel/NF-κB signaling contributes to human cancer, and that this pathway will continue to receive attention as a promising molecular target for cancer therapy and prevention. However, there remain many molecular details to resolve. Moreover, at least in some cases, constitutive p50-RELA activity may be an adaptation of certain tumor cell lines to growth in tissue culture or may be a symptom of an abnormal, tumor-induced differentiation program. For example, Cogswell et al. (2000) found that primary human breast cancer tumor cells have active p52, REL, and BCL-3, whereas breast cancer cell lines have constitutively active RELA. Consistent with that finding, over-expression of RELA reduces the tumorigenicity of one breast cancer cell line in vivo (Ricca et al., 2001). Finally, given that the Rel/NF-κB pathway can have opposite effects on growth and apoptosis in different cell types, all cancers may not respond in the same way to inhibition of the NF-κB pathway. Indeed, overexpression of the IκBα super-repressor promotes skin carcinomas in one transgenic mouse model system (van Hogerlinden et al., 1999). Thus, the growth and survival of a given tumor cell type is likely to depend on a balance between the activity of the Rel/NF-κB pathway and the activity of many other signaling pathways in ways that are not always easy to predict. In addition, as documented in this collection of articles, it is likely that the Rel/NF-κB pathway is only one of several signaling pathways that are commonly activated in human cancers" @default.
• W2262425995 created "2016-06-24" @default.
• W2262425995 creator A5042073445 @default.
• W2262425995 date "2006-02-27" @default.
• W2262425995 modified "2023-10-17" @default.
• W2262425995 title "The Rel/NF-κB/IκB Signal Transduction Pathway and Cancer" @default.
• W2262425995 cites W1501881225 @default.
• W2262425995 cites W1504653733 @default.
• W2262425995 cites W1507924380 @default.
• W2262425995 cites W1535776410 @default.
• W2262425995 cites W1558367558 @default.
• W2262425995 cites W1558901013 @default.
• W2262425995 cites W1580723864 @default.
• W2262425995 cites W1583003179 @default.
• W2262425995 cites W1814410326 @default.
• W2262425995 cites W1846940228 @default.
• W2262425995 cites W1914674710 @default.
• W2262425995 cites W1963906419 @default.
• W2262425995 cites W1965637582 @default.
• W2262425995 cites W1966283393 @default.
• W2262425995 cites W1967134457 @default.
• W2262425995 cites W1967742670 @default.
• W2262425995 cites W1977872674 @default.
• W2262425995 cites W1981380902 @default.
• W2262425995 cites W1981619472 @default.
• W2262425995 cites W1982047106 @default.
• W2262425995 cites W1982062664 @default.
• W2262425995 cites W1983771472 @default.
• W2262425995 cites W1987099700 @default.
• W2262425995 cites W1987531976 @default.
• W2262425995 cites W1988356885 @default.
• W2262425995 cites W1989844987 @default.
• W2262425995 cites W1992617765 @default.
• W2262425995 cites W2003071187 @default.
• W2262425995 cites W2004391147 @default.
• W2262425995 cites W2006929818 @default.
• W2262425995 cites W2011007912 @default.
• W2262425995 cites W2013513313 @default.
• W2262425995 cites W2017877447 @default.
• W2262425995 cites W2023877008 @default.
• W2262425995 cites W2025504025 @default.
• W2262425995 cites W2026863172 @default.
• W2262425995 cites W2029278007 @default.
• W2262425995 cites W2032531389 @default.
• W2262425995 cites W2033624366 @default.
• W2262425995 cites W2037095349 @default.
• W2262425995 cites W2040638887 @default.
• W2262425995 cites W2046265685 @default.
• W2262425995 cites W2051515686 @default.
• W2262425995 cites W2051994734 @default.
• W2262425995 cites W2057324653 @default.
• W2262425995 cites W2058145374 @default.
• W2262425995 cites W2058705034 @default.
• W2262425995 cites W2059902938 @default.
• W2262425995 cites W2064201629 @default.
• W2262425995 cites W2064208261 @default.
• W2262425995 cites W2065578770 @default.
• W2262425995 cites W2066840473 @default.
• W2262425995 cites W2067175003 @default.
• W2262425995 cites W2069158176 @default.
• W2262425995 cites W2080070482 @default.
• W2262425995 cites W2084336363 @default.
• W2262425995 cites W2086189875 @default.
• W2262425995 cites W2086941505 @default.
• W2262425995 cites W2087078985 @default.
• W2262425995 cites W2093813815 @default.
• W2262425995 cites W2093877091 @default.
• W2262425995 cites W2095777941 @default.
• W2262425995 cites W2098953839 @default.
• W2262425995 cites W2103856686 @default.
• W2262425995 cites W2103944436 @default.
• W2262425995 cites W2106877484 @default.
• W2262425995 cites W2107445646 @default.
• W2262425995 cites W2111642458 @default.
• W2262425995 cites W2115648461 @default.
• W2262425995 cites W2116487940 @default.
• W2262425995 cites W2117327528 @default.
• W2262425995 cites W2118833233 @default.
• W2262425995 cites W2118986158 @default.
• W2262425995 cites W2121652706 @default.
• W2262425995 cites W2129242841 @default.
• W2262425995 cites W2130436812 @default.
• W2262425995 cites W2132218438 @default.
• W2262425995 cites W2136426653 @default.
• W2262425995 cites W2140279511 @default.
• W2262425995 cites W2140288732 @default.
• W2262425995 cites W2147013585 @default.
• W2262425995 cites W2147246240 @default.
• W2262425995 cites W2147921405 @default.
• W2262425995 cites W2152044329 @default.
• W2262425995 cites W2152105216 @default.
• W2262425995 cites W2157676659 @default.
• W2262425995 cites W2165696541 @default.
• W2262425995 cites W2169058970 @default.
• W2262425995 cites W2169989829 @default.
• W2262425995 cites W2171865516 @default.
• W2262425995 cites W2172184160 @default.
• W2262425995 cites W2182057534 @default.

• next